Cascadian Therapeutics
Apr 5, 2017

Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017

Preclinical data from Chk1 inhibitor program and first presentation characterizing lead TIGIT antibody

SEATTLE, April 05, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced data highlights from presentations of preclinical data for the Company's investigational orally bioavailable, potent and selective checkpoint kinase 1 (Chk1) inhibitor known as CASC-578. An additional abstract highlights data from the first public presentation on the Company's preclinical antibody program targeting the immune checkpoint receptor TIGIT. These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, DC from April 1-5, 2017.

"The research presented at AACR illustrates why we believe CASC-578 is well positioned for IND-enabling studies," said Scott Peterson, Ph.D., Chief Scientific Officer of Cascadian Therapeutics. "CASC-578 has demonstrated anti-tumor activity as a single agent or in combination with a Wee1 inhibitor in preclinical models of acute leukemia, mantle cell lymphoma and non-small cell lung cancer. Furthermore, a recent GLP safety pharmacology study indicated CASC-578 has an acceptable safety profile with no apparent effects on QTc interval or cardiac contractility."

Dr. Peterson added, "Our TIGIT antibody program presentation profiles the discovery of highly potent, fully human TIGIT antibodies, which are active as a single agent in a mouse tumor model that is resistant to PD-1 antibody blockade."

A summary of data highlights presented at AACR follows. To access these poster presentations, please visit www.cascadianrx.com.

CASC-578, a novel Chk1 inhibitor, is active as a single agent in solid tumors and displays synergistic anti-tumor activity in combination with Wee1 inhibition (Abstract #295)

CASC-578 is a highly selective, picomolar inhibitor of Chk1 that is active as a single agent and in combination with chemotherapeutic agents in a variety of solid tumor and hematological tumor derived cell lines. Chk1 is a protein kinase that regulates cell cycle progression in response to DNA damage response (DDR) signaling.

The novel orally available sub-nanomolar potent and selective checkpoint kinase 1 inhibitor CASC-578 is highly active in mantle cell lymphoma as a single agent and in combination with Wee1 inhibition (Abstract #297)

Preclinical pharmacokinetics of CASC-578, a novel selective potent and orally bioavailable small molecule checkpoint kinase 1 inhibitor (Abstract #4090)  

Discovery and characterization of novel antagonistic antibodies that bind with high affinity to human, cynomolgus and murine TIGIT, an immune checkpoint receptor (Abstract #578)

TIGIT is an emerging immune checkpoint target that regulates the induction of adaptive (T cell) and innate (natural killer or NK) cells. CASC-TIGIT antibodies represent a potentially attractive approach to immune checkpoint inhibition.

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind, controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov. For more information, please visit www.cascadianrx.com.

Forward-Looking Statements

In order to provide Cascadian Therapeutics' investors with an understanding of its current results and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Cascadian Therapeutics' expectations regarding clinical development activities, and the potential benefits of CASC-578 and CASC-TIGIT antibodies. Forward-looking statements involve risks and uncertainties related to Cascadian Therapeutics' business and the general economic environment, many of which are beyond its control. These risks, uncertainties and other factors could cause Cascadian Therapeutics' actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing its product candidates, the adequacy of financing and cash, cash equivalents and investments, changes in general accounting policies, general economic factors, achievement of the results it anticipates from its preclinical development and clinical trials of its product candidates and its ability to adequately obtain and protect its intellectual property rights. Although Cascadian Therapeutics believes that the forward-looking statements contained herein are reasonable as of the date hereof, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of Cascadian Therapeutics' risks and uncertainties, you should review the documents filed by Cascadian Therapeutics with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Cascadian Therapeutics does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by law.

Investor and Media Contact:
Monique Greer
Cascadian Therapeutics
206-801-2107
mgreer@cascadianrx.com